hotspot -WSS

hotspot

author：explore 2025-09-30 17:45:05 - browse：2135

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Prescription digital therapeutics are key to pharma’s future

WSS

UpToDate has a racism problem: Dr. Stanley Goldfarb

Beware reading your test results before your doctor does

Dexcom's push to bring CGM to type 2 diabetes patients

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

What it’s like to watch children die of measles

'Screen and refer' systems are hurting patients

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Use doctors trained outside the U.S. to ease the physician shortage

Medical records are filled with copy

Fatty liver disease was alleviated by Lilly’s ‘triple

Trump demands the U.S. pay no more for drugs than other countries … again

The Readout: Amylyx, Alumis, and Lundbeck drug updates

As demand for Covid shots wanes, Moderna seeks its next success

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Tori Bowie and the unacceptable rates of Black maternal death

How to bring more disabled researchers into academia

hotspot

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Fatty liver disease was alleviated by Lilly’s ‘triple

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Drug cartel violence flares in western Mexico after vigilante leader's killing

How Robert F. Kennedy Jr. distorted vaccine science

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

knowledge

explore

entertainment

focus